$aTyr Pharma(LIFE.US)$ Management highlighted plans to launch the ATYR1923 PH3 trial in pulmonary sarcoidosis in 2022. The company will also present additional preclinical data from ATYR2810 at SITC 2021 tomorrow and plans to move ATYR2810 into clinical trials next year. Recent attention has focused on the ph3 trial design conducted after the company's meeting with the FDA.
$aTyr Pharma(LIFE.US)$ Following successful completion of PH2, aTyr plans to hold a meeting with FDA to discuss the PH3 study design as soon as possible, and data release is in the works. The company recently announced a collaboration with Ohio State University to develop a companion diagnosis as a predictive biomarker for granuloma formation to identify better responders to ATRY1923 in pulmonary sarcoidosis.
$aTyr Pharma(LIFE.US)$A dip at open to 11.30 would mean a run up to 12.60. Has to stay above 10.82 tho. May have enough support to only dip to 11.47 then run to 12.60.
aTyr Pharma股票討論區
🚀
Fcking genius alert is better than paid discords 🤑🤑🤑🚀🚀🚀 alerted bottoms 1.07
Load this shit up next month gonna be massive squeeze
Management highlighted plans to launch the ATYR1923 PH3 trial in pulmonary sarcoidosis in 2022. The company will also present additional preclinical data from ATYR2810 at SITC 2021 tomorrow and plans to move ATYR2810 into clinical trials next year. Recent attention has focused on the ph3 trial design conducted after the company's meeting with the FDA.
Hold or sell
I bought at 9.8 .last 2 weeks it is hovering around 9 .any chance of break even?
Following successful completion of PH2, aTyr plans to hold a meeting with FDA to discuss the PH3 study design as soon as possible, and data release is in the works. The company recently announced a collaboration with Ohio State University to develop a companion diagnosis as a predictive biomarker for granuloma formation to identify better responders to ATRY1923 in pulmonary sarcoidosis.
Stocks with no short shares available and high interest
暫無評論